Patch-based electrocardiogram sensor
Intervention1 paper2 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
Funder: Helse Sør-Øst RHF2 of 2 findings with company ties
- Human trial1
Associations
2Anticoagulation therapy
upin humans1
1 study
Anticoagulation therapy
upin humans1
Patch-based electrocardiogram sensor is associated with anticoagulation therapy in humans (95.8% (366 of 382)).
Human trialparticipants with screen-detected AFn = 382
Digital recruitment and prevalence of screen-detected atrial fibrillation in nationwide patch-based ECG screening: the NORSCREEN randomized clinical trial · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 4 Aug 2026
Atrial fibrillation
upin humans1
1 study
Atrial fibrillation
upin humans1
Patch-based electrocardiogram sensor predicts atrial fibrillation in humans (1.9% (382 of 19,723)).
Human trialat-risk individuals with ≥1 stroke risk factor7 daysn = 19,723
Digital recruitment and prevalence of screen-detected atrial fibrillation in nationwide patch-based ECG screening: the NORSCREEN randomized clinical trial · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 4 Aug 2026